此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

癌症护理精确运动方案(PERCC)研究的飞行员研究 (PILOT PERCC)

2026年10月30日 更新者:University of Utah

This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.

研究概览

详细说明

This is a pilot study evaluating the feasibility of the Precision Exercise Regimen for Cancer Care (PERCC) intervention in stage II and stage III Non-Small Cell Lung Cancer (NSCLC) patients receiving multimodal therapy at the Huntsman Cancer Institute (HCI) at the University of Utah. Eligible patients will begin the intervention at the pre-treatment clinic visit and continue until approximately two months post-surgery.

The PERCC intervention is a virtually supervised home-based exercise program. Participants will engage in exercise starting at least two weeks before receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment. The exercise modes will include basic transfer and calisthenics mobility, aerobic, and resistance exercises and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting).

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Texas
      • Galveston、Texas、美国、77555
        • 招聘中
        • University of Texas Medical Branch at Galveston
        • 接触:
    • Utah
      • Salt Lake City、Utah、美国、84112
        • 招聘中
        • Huntsman Cancer Institute
        • 接触:
        • 首席研究员:
          • Thomas Varghese, MD, MS, MBA, FACS

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ages 18 and older at time of diagnosis
  • Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
  • Patient receives neoadjuvant therapy (defined as chemotherapy, radiation therapy immunotherapy, or any combination of these modalities) and surgery
  • Patient able to follow direction and complete questionnaires in English or Spanish
  • Patient agrees to complete the PERCC intervention

Exclusion Criteria:

  • Morbidly obese (BMI >40 kg/m2 ) or anorexic (BMI <17.5 kg/m2 )
  • Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
  • Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
  • Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Precision Exercise Regimen for Cancer Care (PERCC)

Participants will engage in PERCC starting at least two weeks prior to receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment.

PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility - Recruitment and Retention
大体时间:up to two months post-surgery

Feasibility of the PERCC intervention will be evaluated by our ability to recruit and retain the needed number of patients with 80% exercise intervention attendance.

up to two months post-surgery

次要结果测量

结果测量
措施说明
大体时间
Feasibility - Safety
大体时间:up to two months post-surgery

The feasibility of the PERCC intervention will be evaluated based on participant safety.

This outcome measure will assess the safety and tolerability of the study treatment.

The severity of AEs will be assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE".

Subjects will be monitored for adverse events from the start of treatment until two months post-surgery.

up to two months post-surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Thomas Varghese, MD, MS, MBA, FACS、Huntsman Cancer Institute

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月21日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2025年4月18日

首先提交符合 QC 标准的

2025年4月18日

首次发布 (实际的)

2025年4月25日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅